Biomakers associated with ventilator associated lung injury

我们研究了几种可以预测急性肺损伤或急性呼吸窘迫综合征（ALI/ARDS）患者死亡率或治疗效果的生物标志物。为此，我们进行了临床和基础研究。在临床研究中，我们在ALI/ARDS患者中采用支气管肺泡微量取样法采集血液和肺泡上皮衬里液。结果，我们发现ALI/ARDS患者的血液和上皮衬里液中层粘连蛋白γ 2链的氨基末端片段的量显著较高。ALI/ARDS组中性内肽酶（NEP）活性明显低于对照组。在基础研究中，我们在类似的肺损伤环境中进行了实验。此外，使用小鼠模型研究了与肺损伤相关的细胞外ATP和膜突蛋白表达。这些研究证实了我们的假设，即这些生物标志物根据疾病的严重程度增加或减少。因此，这些生物标志物应该在更大规模的临床试验中检查是否对医生有用。

We studied several biomarkers that could predict the mortality or efficacy of therapy in patients with acute lung injury or acute respiratory distress syndrome (ALI/ARDS). For this aim, we conducted clinical and basic studies. In clinical studies, we sampled blood and alveolar epithelial lining fluid which was facilitated by the method of bronchoalveolar microsampling in ALI/ARDS patients. As a result, we found significantly higher amount of amino-terminal fragment of laminin gamma2-chain in blood and in epithelial lining fluids of patients with ALI/ARDS. And also, neutral endopeptidase (NEP) activity in ALI/ARDS patients were significantly lower compared to control group. In basic studies we conducted the experiments in similar lung injurious settings. In addition, extracellular ATP and moesin expression in association with lung injury were studied using mouse model. These studies confirmed our hypothesis that these biomarkers increase or decrease in accordance with the severity of the disease. Thus these biomarkers should be examined in a larger clinical trial whether it could useful for the physicians.